The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
RegeNovar: A phase I/II study of ubamatamab plus carboplatin, paclitaxel, and bevacizumab as salvage therapy in ovarian cancer with poor response to first-line chemotherapy.
 
Benoit You
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Clovis Oncology; Daiichi Sankyo Europe GmbH; ECS PROGASTRIN; Eisai; GlaxoSmithKline; Immunomedics; LEK; MSD Oncology; Myriad Genetics; Novartis; Pharma&; Roche/Genentech; Seagen; TESARO
Research Funding - Clovis Oncology (Inst); Merck Serono (Inst); NOVARTIS (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; BMS; MSD Oncology; Roche/Genentech; SEAGEN
 
Coriolan Lebreton
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; MSD Oncology; pharmaand (Inst); Regeneron
Consulting or Advisory Role - Abbvie; AstraZeneca
Travel, Accommodations, Expenses - GlaxoSmithKline; MSD Oncology; PharmaAnd
 
Fabien Subtil
No Relationships to Disclose
 
Aurore Carrot
No Relationships to Disclose
 
Jean-Sebastien Frenel
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca (Inst); Clovis Oncology (Inst); Daiichi Sankyo Europe GmbH (Inst); Eisai; Exact Sciences (Inst); Gilead Sciences; GlaxoSmithKline; Lilly; MSD Oncology (Inst); Novartis (Inst); Pfizer; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Europe GmbH; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; seagen
 
Leila Bengrine-Lefevre
No Relationships to Disclose
 
Lauriane Eberst
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; MSD/AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; MSD
 
Brunhilde Hanvic
Travel, Accommodations, Expenses - pharma&
 
Renaud Sabatier
Honoraria - AstraZeneca; Eisai Europe; GlaxoSmithKline; MSD Oncology
Consulting or Advisory Role - Abbvie; GlaxoSmithKline; MSD Oncology
Speakers' Bureau - GlaxoSmithKline; Pharma&; Seagen
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Eisai Europe; GlaxoSmithKline; MSD Oncology; Novartis
 
Coraline Dubot
Speakers' Bureau - Eisai; GlaxoSmithKline; MSD Oncology
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Eisai; MSD Oncology; pharma&
 
Stanislas Quesada
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline
Travel, Accommodations, Expenses - AstraZeneca; Eisai; GlaxoSmithKline; MSD
 
Alexandra Leary
Honoraria - Gerson Lehrman Group; Medscape; peervoice
Consulting or Advisory Role - Abbvie (Inst); Apmonia Therapeutics (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Merck Serono (Inst); MSD (Inst); PEGASCY; Pharmend (Inst); Seagen (Inst); Tesaro (Inst); zentalis (Inst)
Research Funding - Adaptimmune (Inst); AstraZeneca (Inst); Inivata (Inst); MSD Oncology (Inst); OSE Immunotherapeutics (Inst); owkin (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Oseimmuno; Tesaro